monarchE Primary OS Results

In this segment, the speakers break down the newly released overall survival results from the monarchE trial, marking the first time OS data have been reported for adjuvant abemaciclib plus endocrine therapy in high-risk HR+, HER2- early breast cancer. The discussion explores the unmet need that led to studying abemaciclib in this setting, the clinical and statistical significance of the 15.8% reduction in risk of death, and the durability of IDFS and DRFS benefits at seven years. The experts also review long-term safety findings, patterns of subsequent therapy use, and the real-world implications of these data—highlighting how this evolving evidence may shape adjuvant treatment decisions for patients at highest risk of recurrence.